Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 1
1948 2
1949 1
1950 1
1951 2
1952 2
1953 1
1954 2
1955 3
1956 5
1957 3
1958 5
1959 5
1960 4
1961 3
1962 7
1963 4
1964 3
1965 16
1966 6
1967 6
1968 11
1969 10
1970 8
1971 9
1972 5
1973 15
1974 8
1975 11
1976 12
1977 13
1978 15
1979 15
1980 14
1981 11
1982 8
1983 11
1984 4
1985 8
1986 14
1987 17
1988 12
1989 25
1990 22
1991 19
1992 17
1993 25
1994 17
1995 13
1996 21
1997 26
1998 18
1999 14
2000 30
2001 23
2002 31
2003 23
2004 38
2005 36
2006 38
2007 41
2008 30
2009 47
2010 49
2011 49
2012 34
2013 36
2014 37
2015 38
2016 38
2017 34
2018 20
2019 31
2020 47
2021 50
2022 52
2023 35
2024 33
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,362 results

Results by year

Filters applied: . Clear all
Page 1
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: katz e. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Brief Resolved Unexplained Events (Formerly Apparent Life-Threatening Events) and Evaluation of Lower-Risk Infants.
Tieder JS, Bonkowsky JL, Etzel RA, Franklin WH, Gremse DA, Herman B, Katz ES, Krilov LR, Merritt JL 2nd, Norlin C, Percelay J, Sapién RE, Shiffman RN, Smith MB; SUBCOMMITTEE ON APPARENT LIFE THREATENING EVENTS. Tieder JS, et al. Among authors: katz es. Pediatrics. 2016 May;137(5):e20160590. doi: 10.1542/peds.2016-0590. Epub 2016 Apr 25. Pediatrics. 2016. PMID: 27244835
Magneto-controlled enzyme reactions.
Bollella P, Katz E. Bollella P, et al. Among authors: katz e. Methods Enzymol. 2020;630:1-24. doi: 10.1016/bs.mie.2019.09.002. Epub 2019 Oct 31. Methods Enzymol. 2020. PMID: 31931981 Review.
Nocturnal Enuresis in the Adult.
Katz EG, MacLachlan LS. Katz EG, et al. Curr Urol Rep. 2020 Jun 6;21(8):31. doi: 10.1007/s11934-020-00983-2. Curr Urol Rep. 2020. PMID: 32506170 Review.
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Marignier R, et al. Among authors: katz e. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33771837 Free PMC article. Clinical Trial.
Biosensors-Recent Advances and Future Challenges.
Bollella P, Katz E. Bollella P, et al. Among authors: katz e. Sensors (Basel). 2020 Nov 20;20(22):6645. doi: 10.3390/s20226645. Sensors (Basel). 2020. PMID: 33233539 Free PMC article.
1,362 results